Table 1.

Therapies and their durations used in the 6 studies included.

#	Study	Citation	Induction Treatment Phase			Maintenance Treatment Phase			Notes
#	Study	Citation	Randomized	Therapy	Mos	Randomized	Therapy	Mos	Notes
1	Chan, et al	13	Yes	CYC	6	No (continued)	AZA	18	Patients who received CYC or MMF within 6 mos before the induction phase were excluded from both treatment phases.
1	Chan, et al	13	Yes	MMF	6	No (continued)	MMF	18
2	Contreras, et al	23	No	CYC	6	Yes	CYC	12–36	Patients who received CYC > 7 doses or AZA > 8 weeks before the induction phase were excluded from both phases.
			No	CYC	6	Yes	AZA	12–36
			No	CYC	6	Yes	MMF	12–36
3	Decker, et al	24	Yes	CYC	3	Yes	CYC	22–25	Therapies switched in 3–12 mos, the rerandomized secondary treatment assignment was held toward the end (see Appendix Tables, available online at jrheum.org).
			Yes	AZA	3	Yes	AZA	22–25
			Yes	Prednisone alone	3	Yes	Prednisone alone	22–25
4	Donadio, et al	22	Yes	AZA	6	No (continued)	AZA	29–43	None.
4	Donadio, et al	22	Yes	Prednisone alone	6	No (continued)	Prednisone alone	25–45
5	Dooley, et al	1	Yes	CYC	6	Yes	AZA	36	Patients who responded to induction treatment were rerandomized for maintenance treatment.
5	Dooley, et al	1	Yes	MMF	6	Yes	MMF	36
6	Houssiau, et al	14	Yes	CYC	3	No (continued)	AZA	33	Designed for maintenance treatment, randomization performed at baseline, but allocation to maintenance treatment irrespective of 3-mo response.
6	Houssiau, et al	14	Yes	CYC	3	No (continued)	MMF	33